Expand DTIL Menu
DTIL MENU

DTIL Latest Press Releases

-- November 19, 2025 --

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 Business Wire 7:01 AM

-- November 10, 2025 --

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants Business Wire 6:12 PM
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts Business Wire 5:22 PM

-- November 3, 2025 --

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update Business Wire 7:01 AM

-- October 31, 2025 --

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 Business Wire 7:01 AM

-- October 14, 2025 --

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2025 Business Wire 7:01 AM

-- October 9, 2025 --

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases Business Wire 7:01 AM

-- October 7, 2025 --

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial Business Wire 7:01 AM

-- October 2, 2025 --

iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting Business Wire 8:00 AM

-- September 30, 2025 --

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society Business Wire 7:01 AM

-- September 12, 2025 --

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium Business Wire 7:01 AM

-- September 8, 2025 --

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status Business Wire 7:01 AM

-- August 25, 2025 --

iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism Business Wire 8:00 AM

-- August 7, 2025 --

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update Business Wire 7:01 AM

-- August 6, 2025 --

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B Business Wire 7:01 AM

-- August 4, 2025 --

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 Business Wire 7:01 AM

-- July 23, 2025 --

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy Business Wire 7:01 AM

-- July 16, 2025 --

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic Business Wire 7:01 AM
Market Data Delayed 15 Minutes